Prenatal NAP+SAL prevents developmental delay in a mouse model of Down syndrome through effects on N-methyl-D-aspartic acid and gamma-aminobutyric acid receptors.

Vink J, Incerti M, Toso L, Roberson R, Abebe D, Spong CY

American journal of obstetrics and gynecology26 Mar 2009Cited by 17 (Europe PMC)

PMID19327737PMCIDPMC6503529DOI10.1016/j.ajog.2009.01.052PepBankPUB-19327737

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Davunetide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Davunetide.

01AnimalNot a test of Davunetide aloneAnimal study (in vivo)Mechanism
In Ts65Dn mice, prenatal NAP plus SAL increased NR2A expression to levels similar to controls.
In plain wordsIn Ts65Dn mice, prenatal NAP plus SAL increased NR2A expression compared with placebo-treated trisomic mice.
Peptide
Davunetide
Outcome
IncreaseNR2A expression
Study
mousen = 7
Ts65Dn Down syndrome model
Comparator
Placebo-treated trisomic mice
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Source sentences
Summary
Prenatal NAP+SAL increased NR2A, NR2B, and GABA(A)beta3 to levels similar to control (all P < .05).
2 context sentences(design, population, supporting numbers)
Summary · context
Pregnant Ts65Dn mice were treated with placebo or NAP+SAL on gestational days 8-12.
Summary · context
After developmental delay prevention was shown, 4 trisomic (Ts), 4 control, and 3 Ts+NAP+SAL adult offspring brains (from 3 litters) were collected.
In this study, Davunetide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Davunetide.
Report a problemFND-1932773701
02AnimalNot a test of Davunetide aloneAnimal study (in vivo)Mechanism
In Ts65Dn mice, prenatal NAP plus SAL increased NR2B expression to levels similar to controls.
In plain wordsIn Ts65Dn mice, prenatal NAP plus SAL increased NR2B expression compared with placebo-treated trisomic mice.
Peptide
Davunetide
Outcome
IncreaseNR2B expression
Study
mousen = 7
Ts65Dn Down syndrome model
Comparator
Placebo-treated trisomic mice
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Source sentences
Summary
Prenatal NAP+SAL increased NR2A, NR2B, and GABA(A)beta3 to levels similar to control (all P < .05).
2 context sentences(design, population, supporting numbers)
Summary · context
Pregnant Ts65Dn mice were treated with placebo or NAP+SAL on gestational days 8-12.
Summary · context
After developmental delay prevention was shown, 4 trisomic (Ts), 4 control, and 3 Ts+NAP+SAL adult offspring brains (from 3 litters) were collected.
In this study, Davunetide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Davunetide.
Report a problemFND-1932773702
03AnimalNot a test of Davunetide aloneAnimal study (in vivo)Mechanism
In Ts65Dn mice, prenatal NAP plus SAL increased GABA(A)beta3 expression to levels similar to controls.
In plain wordsIn Ts65Dn mice, prenatal NAP plus SAL increased GABA(A)beta3 expression compared with placebo-treated trisomic mice.
Peptide
Davunetide
Outcome
IncreaseGABA(A)beta3 expression
Study
mousen = 7
Ts65Dn Down syndrome model
Comparator
Placebo-treated trisomic mice
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Source sentences
Summary
Prenatal NAP+SAL increased NR2A, NR2B, and GABA(A)beta3 to levels similar to control (all P < .05).
2 context sentences(design, population, supporting numbers)
Summary · context
Pregnant Ts65Dn mice were treated with placebo or NAP+SAL on gestational days 8-12.
Summary · context
After developmental delay prevention was shown, 4 trisomic (Ts), 4 control, and 3 Ts+NAP+SAL adult offspring brains (from 3 litters) were collected.
In this study, Davunetide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Davunetide.
Report a problemFND-1932773703
04AnimalNot a test of Davunetide aloneAnimal study (in vivo)Efficacy outcome
In Ts65Dn mice, prenatal NAP plus SAL prevented developmental delay before adult brain analysis.
In plain wordsIn Ts65Dn mice, prenatal NAP plus SAL prevented developmental delay compared with placebo-treated trisomic mice.
Peptide
Davunetide
Outcome
DecreaseDevelopmental delay
Study
mousen: not reported in source
Ts65Dn Down syndrome model
Comparator
Placebo-treated trisomic mice
Outcome group
Cognition and memory · Nervous system and cognition
Source sentences
Summary
After developmental delay prevention was shown, 4 trisomic (Ts), 4 control, and 3 Ts+NAP+SAL adult offspring brains (from 3 litters) were collected.
1 context sentence(design, population, supporting numbers)
Summary · context
Pregnant Ts65Dn mice were treated with placebo or NAP+SAL on gestational days 8-12.
In this study, Davunetide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Davunetide.
Report a problemFND-1932773704

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.